Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

TORONTO, July 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the second fiscal quarter of 2008, ended May 31st, 2008.

"Throughout the second quarter, we maintained our focus on moving ARIUS' anti-cancer antibodies towards human clinical trial. Most notably, our lead drug candidates received significant attention from the scientific community this quarter as five abstracts were presented at the AACR Annual Meeting in April, disclosing new findings about our CD44, Trop-2, CD59, and CD9 antibody programs," said Dr. David Young, President and CEO of ARIUS. "Additionally, abstracts on our CD44 program were selected for publication at the ASCO Annual Meeting in May. The inclusion of ARIUS' findings at these important conferences demonstrates the high quality of our research and reinforces the value of our lead drug candidates."

Program Updates:

CD44 Cancer Stem Cell Program

- Presented two CD44-focused posters at AACR the American Association

for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008

in San Diego, California.

- Published two CD44-focused abstracts at the American Association for

Clinical Oncology (ASCO) Annual Meeting held from May 30-June 3, 2008

in Chicago, Illinois.

- Held meeting with FDA to discuss plans for the upcoming IND

submission in the first quarter of 2008.

- ARIUS plans to have clinical trials' materials prepared in the fourth

quarter of 2008 and then a Phase I IND application is expected to be

filed and human clinical trials commenced.

Trop-2 Signal Transduction Program

- Completed two toxicology studies with no dose-limiting toxicity.

- Presented a Trop-2-focused poster at AACR Annual Meeting.

- Engaged
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Portfolio of Regenerative TreatmentsNEW YORK, May 11, NeoStem, ... pioneering the pre-disease collection, processing and long-term storage of ... it has signed an exclusive royalty-bearing license agreement for ... rapidly grows a patient,s own adult stem cells to ...
... /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... from a randomized Phase 2 trial evaluating OGX-011 ... first-line chemotherapy in patients with metastatic castration-resistant prostate ... at the American Society of Clinical Oncology (ASCO) ...
... European alliances and gears up for business at world,s major chemical ... ... (Vocus) May 11, 2009 -- The Northern Ireland based manufacturer of ... is boosting its European distribution network ahead of its attendance ...
Cached Biology Technology:NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases 2NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases 3NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases 4OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 2OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting 3Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 2Pharmaceutical Packaging Equipment Manufacturer Boosts European Distribution 3
(Date:10/15/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" ... mobile commerce market releases photos and video of the recent opening ... 13 th . Gino Pereira , CEO ... investor Mr. Chad A. Verdi rang the bell.  ... investors and employees "for their work and dedication in bringing the ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
(Date:10/14/2014)... a new kind of stem cell that can become either ... vessels, according to a study published today in the journal ... cell type contradicts current theory on how organs arise from ... origins of, and future treatment for, liver cancer., Thanks to ... complex being made up of more than 200 cell types. ...
Breaking Biology News(10 mins):Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... around biological data from electronic tags, ear bone microchemistry and ... one side of the Atlantic influences the other side. ... declined precipitously since 1950, according to the study published today ... The model estimates the number of Atlantic bluefin tuna remaining ...
... peer-reviewed scientific studies of the effects on wildlife of ... adequately assess their impact, especially in the desert Southwest, ... U.S. Geological Survey and published in the journal ... of the paper, USGS scientist Jeffrey Lovich and Maryville ...
... oil spill in the Gulf of Mexico, the U.S. ... Engineering and National Research Council to convene a committee ... disaster and identify measures for preventing similar harm in ... IMPROVING OFFSHORE DRILLING SAFETY, the committee,s final report, analyzes ...
Cached Biology News:New study provides comprehensive view of the status of Atlantic bluefin tuna 2New study provides comprehensive view of the status of Atlantic bluefin tuna 3Literature review on solar energy and wildlife impacts research 2
... GenePix Professional 4200A can be upgraded to ... automatically loads, scans, analyzes, and saves results ... you by email when the batch is ... even for warped slides. GenePix Pro gives ...
... the value of your microarray data using ... you need from consultation to extensive data ... methods. Utilize our expertise in combination with ... your own microarray experiments., ,Normalization and basic ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: